Effect of Osimertinib in Combination With Chemotherapy and Bevacizumab for Untreated Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer: Case Report

• 主要な著者: Haifeng Qin (著者), Fang Wang (著者), Zhen Zeng (著者), Suting Jia (著者), Yuan Liu (著者), Hongjun Gao (著者)
• フォーマット: 図書
• 出版事項: Frontiers Media S.A., 2021-07-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

Introduction: Osimertinib is an oral, third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations. However, whether patients with EGFR mutations can be treated by osimerti...